SYDNEY, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (Recce or the Company), a leading developer of a new class of synthetic anti-infectives, today announced ...

For example, the Recce Pharmaceuticals Ltd (ASX:RCE) share price is up a whopping 413% in the last half decade, a handsome return for long term holders. And this is just one example of the epic ...

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor ...

Following the raise, Recce will have a pro-forma cash position of $16m. This excludes an R&D rebate expected from the ATO in Q4 2025 of ~$8.5m and a further $10m in anticipated non-dilutive ...

Recce Pharmaceuticals (ASX:RCE) has secured the first tranche of a $30 million debt facility to continue running skin infection trials and boost commercialisation efforts across the ASEAN region ...

Recce Pharmaceuticals raises $15.8 million to advance its Phase 3 trials for its topical gel treatment in Indonesia and Australia. Stockhead TV less than 2 min read June 6, 2025 - 6:20AM ...

Recce establishes debt facility of up to ~$30m with Avenue Capital Group Initial non-dilutionary funding of ~$11.5m supporting two registrational Phase III clinical trials Debt facility builds on ...

Stockhead TV less than 2 min read June 6, 2025 - 6:50AM Stockhead Long Shortz: Recce Pharmaceuticals ...

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health ...

Following the raise, Recce will have a pro-forma cash position of $16m. This excludes an R&D rebate expected from the ATO in Q4 2025 of ~$8.5m and a further $10m in anticipated non-dilutive ...